Corcept Therapeutics (CORT) EBIT (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of EBIT data on file, last reported at -$49.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 1552.02% year-over-year to -$49.6 million; the trailing twelve-month figure through Mar 2026 stood at -$8.2 million (down 107.41% YoY), and the FY2025 full-year result was $44.8 million, down 67.29% from the prior year.
• EBIT retreated to -$49.6 million in Q1 2026, from $4.5 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $46.6 million in Q3 2024 to a low of -$49.6 million in Q1 2026.
• A 5-year average of $20.7 million and a median of $26.8 million in 2022 frame the typical range for EBIT.
• Across the five-year window, EBIT surged 98.61% in 2024 and sank 1552.02% in 2026, its largest moves.
• Tracing CORT's EBIT over 5 years: stood at $22.5 million in 2022, then jumped by 40.76% to $31.7 million in 2023, then declined by 20.23% to $25.3 million in 2024, then slumped by 82.24% to $4.5 million in 2025, then sank by 1205.44% to -$49.6 million in 2026.
• Business Quant data shows CORT's EBIT at -$49.6 million in Q1 2026, $4.5 million in Q4 2025, and $10.2 million in Q3 2025.